Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 30, 2026, 2:01 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 265–288 of 1,364 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: Syringe Clear all
Completed Phase 1 Interventional Accepts healthy volunteers

A Study in Healthy Adult Participants to Assess the Pharmacokinetics, Immunogenicity, Safety, and Tolerability of a Ravagalimab Subcutaneous Formulation in a Pre-Filled Syringe

NCT06402513
View directory record Official record
Conditions
Healthy Volunteers
Interventions
Ravagalimab
Drug
Lead sponsor
AbbVie
Industry
Eligibility
18 Years to 65 Years
Enrollment
12 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2024
U.S. locations
1
States / cities
Grayslake, Illinois
Source: ClinicalTrials.gov public record
Updated Oct 21, 2024 · Synced Oct 30, 2026, 2:01 PM EDT
Completed Not applicable Interventional Results available

A Randomized Trial of Vaccine Adherence in Young Injection Drug Users

NCT00244374
View directory record Official record
Conditions
Medication Adherence, Substance Abuse, Intravenous, Risk Behavior, Hepatitis A, Hepatitis B, Hepatitis C
Interventions
Hepatitis A & B vaccine, Outreach, AIC, SEP
Biological · Behavioral
Lead sponsor
University of California, San Francisco
Other
Eligibility
14 Years to 29 Years
Enrollment
546 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2008
U.S. locations
1
States / cities
San Francisco, California
Source: ClinicalTrials.gov public record
Updated Sep 30, 2013 · Synced Oct 30, 2026, 2:01 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Study to Evaluate the Safety, Tolerability, and PK in Healthy Volunteers and HCV Genotype 1 Infected Patients

NCT01523990
View directory record Official record
Conditions
Healthy, Hepatitis C, Chronic
Interventions
TG-2349, placebo
Drug
Lead sponsor
TaiGen Biotechnology Co., Ltd.
Industry
Eligibility
18 Years to 65 Years
Enrollment
135 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2011 – 2013
U.S. locations
1
States / cities
Cypress, California
Source: ClinicalTrials.gov public record
Updated Dec 19, 2014 · Synced Oct 30, 2026, 2:01 PM EDT
Terminated Phase 1 Interventional

LMP2a-Specific Cytotoxic T-Lymphocytes, Lymphoma (ACDAL)

NCT00082225
View directory record Official record
Conditions
Lymphoma
Interventions
CD45 antibodies, EBV specific T cells
Biological
Lead sponsor
Baylor College of Medicine
Other
Eligibility
Not listed
Enrollment
4 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2008
U.S. locations
2
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Feb 7, 2017 · Synced Oct 30, 2026, 2:01 PM EDT
Withdrawn Phase 3 Interventional Accepts healthy volunteers

Plasma Glucose Levels With Dexamethasone as Adjuvant to Interscalene Block

NCT01538459
View directory record Official record
Conditions
Shoulder Pain, Injury of Shoulder Region, Disorder of Shoulder, Disorder of Rotator Cuff, Disorder of Tendon of Biceps
Interventions
Dexamethasone, Bupivacaine
Drug
Lead sponsor
Lifespan
Other
Eligibility
18 Years to 75 Years
Healthy volunteers
Accepts healthy volunteers
Timeline
2012 – 2013
U.S. locations
1
States / cities
Newport, Rhode Island
Source: ClinicalTrials.gov public record
Updated May 20, 2013 · Synced Oct 30, 2026, 2:01 PM EDT
Enrolling by invitation Not applicable Interventional Accepts healthy volunteers

External Nitric Oxide Measurement Through SNO Degradation

NCT04903535
View directory record Official record
Conditions
Healthy, Unconscious
Interventions
Alonefire SV003 10W 365nm UV Flashlight
Device
Lead sponsor
Indiana University
Other
Eligibility
1 Day to 75 Years
Enrollment
150 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2026
U.S. locations
2
States / cities
Indianapolis, Indiana
Source: ClinicalTrials.gov public record
Updated Feb 9, 2026 · Synced Oct 30, 2026, 2:01 PM EDT
Terminated Phase 3 Interventional Results available

Tranexamic Acid Use to Reduce Blood Transfusion in Pediatric Cancer Patients Undergoing Limb Salvage Procedure

NCT04410042
View directory record Official record
Conditions
Cancer of the Bone, Limb Salvage
Interventions
Tranexamic Acid, 0.9% sodium chloride
Drug · Other
Lead sponsor
St. Jude Children's Research Hospital
Other
Eligibility
Up to 24 Years
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2024
U.S. locations
1
States / cities
Memphis, Tennessee
Source: ClinicalTrials.gov public record
Updated Dec 20, 2024 · Synced Oct 30, 2026, 2:01 PM EDT
Completed Not applicable Interventional

The Impact of Holding on Stress and Bonding in Mother-Infant Pairs During Therapeutic Hypothermia

NCT03837717
View directory record Official record
Conditions
Hypoxic-Ischemic Encephalopathy, Neonatal Encephalopathy
Interventions
Holding, Saliva collection, No Holding
Behavioral · Other
Lead sponsor
MaineHealth
Other
Eligibility
24 Hours to 2 Days
Enrollment
34 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2021
U.S. locations
1
States / cities
Portland, Maine
Source: ClinicalTrials.gov public record
Updated Dec 17, 2021 · Synced Oct 30, 2026, 2:01 PM EDT
Completed Phase 1 Interventional Results available

A Multiple Ascending Dose Trial Investigating Safety, Tolerability and Pharmacokinetics of NNC0361-0041

NCT04279613
View directory record Official record
Conditions
Type I Diabetes
Interventions
NNC0361-0041, Placebo
Drug · Other
Lead sponsor
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
NIH
Eligibility
18 Years to 45 Years
Enrollment
47 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2024
U.S. locations
16
States / cities
Orange, California • San Francisco, California • Stanford, California + 13 more
Source: ClinicalTrials.gov public record
Updated May 20, 2025 · Synced Oct 30, 2026, 2:01 PM EDT
Completed Phase 3 Interventional Results available

Anemia Studies in Chronic Kidney Disease (CKD): Erythropoiesis Via a Novel Prolyl Hydroxylase Inhibitor (PHI) Daprodustat-in Incident Dialysis (ASCEND-ID)

NCT03029208
View directory record Official record
Conditions
Anaemia
Interventions
Daprodustat, Darbepoetin alfa, Iron therapy
Drug
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
18 Years to 99 Years
Enrollment
312 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2020
U.S. locations
36
States / cities
Anaheim, California • Cerritos, California • Escondido, California + 31 more
Source: ClinicalTrials.gov public record
Updated Oct 20, 2021 · Synced Oct 30, 2026, 2:01 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers Results available

A Study of Galcanezumab in Healthy Participants.

NCT02836613
View directory record Official record
Conditions
Healthy
Interventions
Galcanezumab
Biological
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
18 Years to 65 Years
Enrollment
160 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2016 – 2017
U.S. locations
3
States / cities
Daytona Beach, Florida • Evansville, Indiana • Dallas, Texas
Source: ClinicalTrials.gov public record
Updated Mar 13, 2019 · Synced Oct 30, 2026, 2:01 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Study of JNJ-70033093 (Milvexian) in Healthy Adult Participants

NCT04844424
View directory record Official record
Conditions
Healthy
Interventions
Milvexian
Drug
Lead sponsor
Janssen Research & Development, LLC
Industry
Eligibility
18 Years to 55 Years
Enrollment
115 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2022
U.S. locations
1
States / cities
Salt Lake City, Utah
Source: ClinicalTrials.gov public record
Updated May 23, 2025 · Synced Oct 30, 2026, 2:01 PM EDT
Completed Phase 4 Interventional Results available

Evaluation of Dexmedetomidine on Post-operative Narcotic Requirements and Pain Scores in Bariatric Patients

NCT02604940
View directory record Official record
Conditions
Pain
Interventions
Dexmedetomidine, Normal Saline
Drug
Lead sponsor
West Virginia University
Other
Eligibility
18 Years to 55 Years
Enrollment
46 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2018
U.S. locations
1
States / cities
Morgantown, West Virginia
Source: ClinicalTrials.gov public record
Updated Jan 17, 2024 · Synced Oct 30, 2026, 2:01 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Study to Evaluate the PK, Relative Bioavailability and Safety of TG-2349 With Single Oral Dose Under Fed Condition in Healthy Volunteers

NCT02108418
View directory record Official record
Conditions
Healthy
Interventions
TG-2349 as the original formulation, TG-2349 as a new capsule formulation
Drug
Lead sponsor
TaiGen Biotechnology Co., Ltd.
Industry
Eligibility
18 Years to 40 Years
Enrollment
24 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2014
U.S. locations
1
States / cities
Cypress, California
Source: ClinicalTrials.gov public record
Updated Dec 19, 2014 · Synced Oct 30, 2026, 2:01 PM EDT
Completed Phase 2 Interventional Results available

A Study of ATH-1017 in Mild to Moderate Alzheimer's Disease

NCT04491006
View directory record Official record
Conditions
Alzheimer Disease, Dementia of Alzheimer Type
Interventions
ATH-1017, Placebo
Drug
Lead sponsor
LeonaBio
Industry
Eligibility
55 Years to 85 Years
Enrollment
77 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2022
U.S. locations
7
States / cities
Santa Ana, California • West Palm Beach, Florida • Decatur, Georgia + 4 more
Source: ClinicalTrials.gov public record
Updated Jun 12, 2023 · Synced Oct 30, 2026, 2:01 PM EDT
Not listed Early Phase 1 Interventional Accepts healthy volunteers

Low-Dose Intravenous Ketamine for Adolescents With Depression and Suicidal Ideation in the Emergency Department

NCT05217706
View directory record Official record
Conditions
Depression, Suicidal Ideation
Interventions
Ketamine, normal Saline
Drug
Lead sponsor
Rady Children's Hospital, San Diego
Other
Eligibility
12 Years to 18 Years
Enrollment
30 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022 – 2024
U.S. locations
1
States / cities
San Diego, California
Source: ClinicalTrials.gov public record
Updated Feb 16, 2023 · Synced Oct 30, 2026, 2:01 PM EDT
Completed Phase 3 Interventional Results available

Randomized Trial of Pegylated Interferon Alfa-2a Versus Hydroxyurea in Polycythemia Vera (PV) and Essential Thrombocythemia (ET)

NCT01259856
View directory record Official record
Conditions
High Risk Polycythemia Vera, High Risk Essential Thrombocythemia
Interventions
PEGASYS, Hydroxyurea, Aspirin
Drug
Lead sponsor
Ronald Hoffman
Other
Eligibility
18 Years and older
Enrollment
168 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2017
U.S. locations
16
States / cities
Scottsdale, Arizona • Los Angeles, California • Palo Alto, California + 10 more
Source: ClinicalTrials.gov public record
Updated Apr 30, 2019 · Synced Oct 30, 2026, 2:01 PM EDT
Recruiting Phase 4 Interventional Accepts healthy volunteers

Effect of Methadone and Hydromorphone on the QT Interval After Anesthesia and Surgery

NCT03893734
View directory record Official record
Conditions
EKG-QT Prolongation
Interventions
methadone, Hydromorphone
Drug
Lead sponsor
Endeavor Health
Other
Eligibility
18 Years to 80 Years
Enrollment
140 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018 – 2020
U.S. locations
1
States / cities
Evanston, Illinois
Source: ClinicalTrials.gov public record
Updated Sep 13, 2019 · Synced Oct 30, 2026, 2:01 PM EDT
Terminated Phase 2 Interventional Results available

Sodium Nitrite in Lung Transplant Patients to Minimize the Risk of Pulmonary Graft Dysfunction

NCT01715883
View directory record Official record
Conditions
Primary Graft Dysfunction
Interventions
Sodium Nitrite
Drug
Lead sponsor
Gladwin, Mark, MD
Individual
Eligibility
18 Years to 70 Years
Enrollment
3 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2017
U.S. locations
1
States / cities
Pittsburgh, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Aug 1, 2018 · Synced Oct 30, 2026, 2:01 PM EDT
Completed Phase 3 Interventional Results available

A Trial to Compare the Efficacy and Safety of Once-weekly Lonapegsomatropin With Placebo and a Daily Somatropin Product in Adults With Growth Hormone Deficiency

NCT04615273
View directory record Official record
Conditions
Growth Hormone Deficiency, Endocrine System Diseases, Hormone Deficiency
Interventions
Lonapegsomatropin, Placebo, Somatropin
Drug · Other
Lead sponsor
Ascendis Pharma Endocrinology Division A/S
Industry
Eligibility
23 Years to 80 Years
Enrollment
264 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2023
U.S. locations
23
States / cities
Birmingham, Alabama • Phoenix, Arizona • Fresno, California + 18 more
Source: ClinicalTrials.gov public record
Updated Jul 7, 2026 · Synced Oct 30, 2026, 2:01 PM EDT
Completed Phase 3 Interventional Results available

Study of Mepolizumab Safety Syringe in Asthmatics

NCT03021304
View directory record Official record
Conditions
Asthma
Interventions
Mepolizumab
Drug
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
12 Years and older
Enrollment
56 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017
U.S. locations
4
States / cities
Birmingham, Alabama • Los Angeles, California • Cincinnati, Ohio + 1 more
Source: ClinicalTrials.gov public record
Updated Jul 23, 2019 · Synced Oct 30, 2026, 2:01 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Pharmacokinetic (PK) Characterization of Subcutaneous Tulisokibart (MK-7240-010)

NCT06575595
View directory record Official record
Conditions
Healthy
Interventions
Tulisokibart
Biological
Lead sponsor
Merck Sharp & Dohme LLC
Industry
Eligibility
18 Years to 55 Years
Enrollment
60 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2024 – 2025
U.S. locations
1
States / cities
Springfield, Missouri
Source: ClinicalTrials.gov public record
Updated Feb 18, 2025 · Synced Oct 30, 2026, 2:01 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers Results available

A Study to Compare the Pharmacokinetics (PK) of Single Subcutaneous (SC) Injections of Vedolizumab Administered in Prefilled Syringe (PFS) Versus (vs) Prefilled Syringe in Autoinjector (PFS+AI) in Healthy Participants

NCT03961308
View directory record Official record
Conditions
Healthy Volunteers
Interventions
Vedolizumab SC
Drug
Lead sponsor
Takeda
Industry
Eligibility
18 Years to 65 Years
Enrollment
204 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018
U.S. locations
2
States / cities
Tempe, Arizona • Lincoln, Nebraska
Source: ClinicalTrials.gov public record
Updated Nov 14, 2019 · Synced Oct 30, 2026, 2:01 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers Results available

A Study of Ixekizumab in Healthy Participants

NCT03848416
View directory record Official record
Conditions
Healthy
Interventions
Ixekizumab
Biological
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
18 Years to 75 Years
Enrollment
99 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019
U.S. locations
1
States / cities
Daytona Beach, Florida
Source: ClinicalTrials.gov public record
Updated Jun 24, 2020 · Synced Oct 30, 2026, 2:01 PM EDT